Safety and Efficacy of Aprepitant for CINV in Patients With Lung Cancer Receiving Multiple-day Cisplatin Chemotherapy

NCT02445872 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Chemotherapy-Induced Nausea and Vomiting
Lung Cancer

Interventions

DRUG: Aprepitant
DRUG: Palonosetron
DRUG: Dexamethasone

Sponsor

Zhejiang University

Collaborators

[object Object]